Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1935 - Multidisciplinary Treatments Increases Overall Survival in Patients with Newly Diagnosed Stage IV Breast Cancer:An Analysis of 2010–2014 SEER Data

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Breast Cancer

Presenters

Jian Zhang

Citation

Annals of Oncology (2019) 30 (suppl_5): v104-v142. 10.1093/annonc/mdz242

Authors

J. Zhang, M. Li, H. Gong

Author affiliations

  • Radiotherapy, Shandong Tumor Hospital, 250117 - Jinan/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1935

Background

Primary treatments for stage IV breast cancer are chemotherapy and endocrine therapy. We sought to determine whether multidisciplinary therapy provides a survival advantage for women with metastatic breast cancer.

Methods

We conducted a population-based cohort study by using the 2010-2014 Surveillance, Epidemiology, and End Results (SEER) program data. By use of the log-rank test and multivariate cox regression models, overall survival in patients was compared between women who underwent different combination modes of surgery, radiotherapy and chemotherapy, controlling for potential confounding demographic, tumor- and treatment-related variables, and propensity scores.

Results

Of 17191 SEER patients with de novo stage IV breast cancer, 29.4% underwent surgery, 32.3% received radiotherapy and 49.6% received chemotherapy. The median follow-up was 28.0 months for all patients. The median survival time of combined surgery, chemotherapy and radiotherapy(SCRT), combined surgery and radiotherapy(SRT),combined surgery and chemotherapy(SC), combined chemotherapy and radiotherapy (CRT), surgery alone, chemotherapy alone, radiotherapy alone and no therapy were 51.0m (95%CI, NR), 46m (95%CI, 39.7-52.3), 37.0m (95%CI, 33.4-40.6), 22.0m (95%CI, 20.0-24.0), 29.0m (95%CI, 25.3-32.7), 26.0m (95%CI, 24.5-27.5), 22.0m (95%CI, 19.9-24.1) and 13.0m (95%CI, 11.8-14.2), respectively (p<0.001). After controlling for potential confounding variables and propensity scores, patients who underwent surgery, radiotherapy and chemotherapy were less likely to die compared with patients who did not undergo surgery, radiotherapy and chemotherapy,respectively (HR = 0.32, 95% CI, 0.30-0.34, p<0.001, HR = 0.40, 95%CI, 0.38-0.43, p<0.001 and HR = 0.51, 95%CI, 0.48-0.54, p<0.001). There was no statistically significant difference among patients with different breast cancer subtype.

Conclusions

Analysis of 2010-2014 SEER data indicated that multidisciplinary approach is especially important in the management of newly diagnosed metastatic breast cancer to consider all potential treatment options for optimal outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Jian Zhang.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.